U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07171034) titled 'A Phase I Study of KLA318-2 Nanocrystal Injection' on Aug. 28.
Brief Summary: The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: KLA318-2 Nanocrystal Injection
Intravenous injection, single dose
DRUG: Celebrex Capsule
P.O., single dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission f...